GlassScriptPhysician profile
Jessica Kaae
NPI 1811335003
$5,921.51
in general payments reported to CMS, 2019-2025
44 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.69 · 2020: $108 · 2021: $191 · 2022: $263 · 2023: $1,417 · 2024: $2,371 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,149 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.88 |
| Education | $122.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $724.66 | 2019-2025 | Rybrevant, Carvykti, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $558.68 | 2023-2025 | Opdivo, Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $556.66 | 2019-2025 | Imfinzi, Tagrisso, Lynparza |
| Exelixis INC. | $286.25 | 2024-2025 | Cabometyx |
| Emd Serono, INC. | $257.64 | 2024 | |
| Amgen INC. | $232.77 | 2021-2025 | Imdelltra (Amg757), Nplate, Xgeva |
| Abbvie INC. | $218.60 | 2024-2025 | |
| Beigene USA, INC. | $215.45 | 2023-2024 | Brukinsa, Tevimbra |
| Tempus Ai, INC | $209.78 | 2024-2025 | Xt Cdx |
| Novartis Pharmaceuticals Corporation | $206.12 | 2023-2024 | |
| Genzyme Corporation | $192.24 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $169.13 | 2021-2023 | Imbruvica |
| Pfizer INC. | $162.15 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $153.25 | 2023-2025 | Clonoseq |
| Kite Pharma, INC. | $138.26 | 2023-2025 | Yescarta |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $125.00 | 2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | |
| Sobi, INC | $117.47 | 2023 | |
| Merck Sharp & Dohme LLC | $104.76 | 2020-2025 | Keytruda, Lynparza |
| US Oncology Corporate, INC. | $95.62 | 2023 | |
| Gilead Sciences, INC. | $95.18 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $91.14 | 2024-2025 | Injectafer, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $77.05 | 2023-2024 | Fruzaqla, Ninlaro |
| Beone Medicines USA, INC. | $76.14 | 2025 | Brukinsa |
| Acrotech Biopharma INC. | $74.72 | 2023-2024 | Beleodaq |
| Genmab U.S., INC. | $58.01 | 2024-2025 | Tivdak |
| Eusa Pharma (US) LLC | $56.22 | 2020-2021 | |
| Astellas Pharma US INC | $50.28 | 2019-2024 | Padcev, Xtandi |
| Sumitomo Pharma America, INC. | $49.76 | 2024-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $44.13 | 2024-2025 | Ojjaara |
| Medtronic, INC. | $33.98 | 2024 | Illumisite |
| Kyowa Kirin, INC. | $33.60 | 2024 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $30.55 | 2023 | |
| Jazz Pharmaceuticals INC. | $25.46 | 2024 | |
| Pharming Healthcare, INC. | $23.82 | 2023 | Ruconest |
| Pharmaessentia USA Corporation | $19.04 | 2024 | Besremi |
| Stemline Therapeutics INC. | $18.15 | 2023 | Orserdu |
| Lilly USA, LLC | $17.80 | 2024 | Jaypirca, Verzenio, Retevmo |
| Exact Sciences Corporation | $17.63 | 2025 | The Cologuard Plus Collection Kit |
| Genentech USA, INC. | $13.83 | 2024 | Alecensa, Tecentriq, Polivy |
| Spectrum Pharmaceuticals INC. | $13.64 | 2024 | Rolvedon |
| Mirati Therapeutics, INC. | $13.53 | 2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $13.36 | 2023 | Fotivda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Kaae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.